In the future, with the discovery of new immune targets and pathways, such as TIGIT and CD155, combination therapies for hepatocellular carcinoma may achieve further breakthroughs, offering improved clinical treatment benefits (59). The gene discussed is PVR; the disease is hepatocellular carcinoma.